Literature DB >> 10400401

Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

P N Maton1, M E Burton.   

Abstract

Antacids are commonly used self-prescribed medications. They consist of calcium carbonate and magnesium and aluminum salts in various compounds or combinations. The effect of antacids on the stomach is due to partial neutralisation of gastric hydrochloric acid and inhibition of the proteolytic enzyme, pepsin. Each cation salt has its own pharmacological characteristics that are important for determination of which product can be used for certain indications. Antacids have been used for duodenal and gastric ulcers, stress gastritis, gastro-oesophageal reflux disease, pancreatic insufficiency, non-ulcer dyspepsia, bile acid mediated diarrhoea, biliary reflux, constipation, osteoporosis, urinary alkalinisation and chronic renal failure as a dietary phosphate binder. The development of histamine H2-receptor antagonists and proton pump inhibitors has significantly reduced usage for duodenal and gastric ulcers and gastro-oesophageal reflux disease. However, antacids can still be useful for stress gastritis and non-ulcer dyspepsia. The recent release of proprietary H2 antagonists has likely further reduced antacid use for non-ulcer dyspepsia. Other indications are still valid but represent minor uses. Antacid drug interactions are well noted, but can be avoided by rescheduling medication administration times. This can be inconvenient and discourage compliance with other medications. All antacids can produce drug interactions by changing gastric pH, thus altering drug dissolution of dosage forms, reduction of gastric acid hydrolysis of drugs, or alter drug elimination by changing urinary pH. Most antacids, except sodium bicarbonate, may decrease drug absorption by adsorption or chelation of other drugs. Most adverse effects from antacids are minor with periodic use of small amounts. However, when large doses are taken for long periods of time, significant adverse effects may occur especially patients with underlying diseases such as chronic renal failure. These adverse effects can be reduced by monitoring of electrolyte status and avoiding aluminum-containing antacids to bind dietary phosphate in chronic renal failure. Antacids, although effective for discussed indications of duodenal and gastric ulcer and gastro-oesophageal reflux disease, have been replaced by newer, more effective agents that are more palatable to patients. Antacids are likely to continue to be used for non-ulcer dyspepsia, minor episodes of heartburn (gastro-oesophageal reflux disease) and other clear indications. Although their wide-spread use may decline, these drugs will still be used, and clinicians should be aware of their potential drug interactions and adverse effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400401     DOI: 10.2165/00003495-199957060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  96 in total

Review 1.  Detergent properties of bile salts: correlation with physiological function.

Authors:  A F Hofmann; D M Small
Journal:  Annu Rev Med       Date:  1967       Impact factor: 13.739

2.  Effect of calcium carbonate and aluminum hydroxide on human intestinal function.

Authors:  D Saunders; J Sillery; R Chapman
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

3.  Antacid side-effects on bowel habits.

Authors:  M Ström
Journal:  Scand J Gastroenterol Suppl       Date:  1982

4.  The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit.

Authors:  M J Zinner; G D Zuidema; M Mignosa
Journal:  Surg Gynecol Obstet       Date:  1981-08

5.  Reduction of twenty-four-hour gastric acidity with combination drug therapy in patients with duodenal ulcer.

Authors:  W L Peterson; C Barnett; M Feldman; C T Richardson
Journal:  Gastroenterology       Date:  1979-11       Impact factor: 22.682

6.  Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer.

Authors:  N Kumar; J C Vij; A Karol; B S Anand
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

7.  Antacid control of complications from acute gastroduodenal disease after burns.

Authors:  J C McAlhany; L Colmic; A J Czaja; B A Pruitt
Journal:  J Trauma       Date:  1976-08

8.  Treatment of duodenal ulcer with low-dose antacids.

Authors:  G Lux; H Hentschel; H G Rohner; H Brunner; K Schütze; P C Lederer; W Rösch
Journal:  Scand J Gastroenterol       Date:  1986-11       Impact factor: 2.423

9.  Cimetidine versus antacids in the prevention of stress erosions in critically ill patients.

Authors:  M H Poleski; A H Spanier
Journal:  Am J Gastroenterol       Date:  1986-02       Impact factor: 10.864

10.  Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial.

Authors:  N Basso; M Bagarani; A Materia; S Fiorani; P Lunardi; V Speranza
Journal:  Am J Surg       Date:  1981-03       Impact factor: 2.565

View more
  27 in total

1.  Antacid effects of Chinese herbal prescriptions assessed by a modified artificial stomach model.

Authors:  Tsung-Hsiu Wu; I-Chin Chen; Lih-Chi Chen
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

2.  Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

Authors:  Kayoko Oda; Ryuichi Iwakiri; Megumi Hara; Kazuyo Watanabe; Akiko Danjo; Ryo Shimoda; Atsushi Kikkawa; Akifumi Ootani; Hiroyuki Sakata; Seiji Tsunada; Kazuma Fujimoto
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 3.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

4.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

5.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.

Authors:  Desmond Padhi; Robert Harris; John T Sullivan
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

7.  Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Authors:  Reza Khosravan; Brian Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

8.  Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Authors:  Edoardo Savarino; Nicola de Bortoli; Patrizia Zentilin; Irene Martinucci; Luca Bruzzone; Manuele Furnari; Santino Marchi; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

9.  Influence of the nanocomposite MgAl-HTlc on gastric absorption of drugs: in vitro and ex vivo studies.

Authors:  Luana Perioli; Pamela Mutascio; Cinzia Pagano
Journal:  Pharm Res       Date:  2012-08-23       Impact factor: 4.200

10.  Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people.

Authors:  Sven E Nilsson; Sanna Takkinen; Boo Johansson; Gerhard Dotevall; Arne Melander; Stig Berg; Gerald McClearn
Journal:  Eur J Clin Pharmacol       Date:  2004-02-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.